ArticleBJC reports2026
MiR-662 impairs C/D box snoRNA expression and rRNA 2'-O-ribose methylation marks.
Article in BJC reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundMiR-662 overexpression has been reported to promote breast cancer metastatic progression and to impair the expression of genes encoding for proteins involved in translation, ribosome biogenesis and ribosome processing (Puppo et al., 2023); however, the relationship between miR-662 and the translational machinery was not further investigated at the time.
methodsMiR-662 was overexpressed in MDA-MB-231-luc2 (NW1) human breast cancer cells. Global protein synthesis was analyzed using polysome profiles. Potential defects in rRNA 47S precursor biogenesis were evaluated by Northern blot. C/D box snoRNA (SNORD) expression was quantified by a medium-throughput RT-qPCR microfluidic dynamic array. rRNA 2'O-ribose methylation (2'Ome) was profiled using RiboMethSeq.
resultsNo changes in rRNA synthesis, processing, or maturation were observed upon miR-662 overexpression. In contrast, a marked reduction in the ratio of polysomal to free ribosomal fractions was observed, indicating an impaired mRNA engagement into translation. Interestingly, a drastic decrease in SNORD levels (but not of their host genes) and a global decrease in rRNA 2'Ome was observed upon miR-662 overexpression.
conclusionsThe involvement of miRNAs in snoRNA-induced modulation in rRNA epitranscriptomic marks might be a novel mechanism of fine regulation of the ribosome composition with possible repercussions on breast cancer metastatic progression.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.